New thrombolytic agents in the treatment of acute myocardial infarction

Medicina Clinica

Volumn 119, Issue 7, 2002, Pages 273-275

  Agustí, Antònia ^a   Arnau, Josep M ^a  

^a Fundacion Institut Catala de Farmacologia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; LANOTEPLASE; RETEPLASE; STREPTOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; FIBRINOLYTIC THERAPY; REVIEW;

CLINICAL TRIALS; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY;

EID: 0037037269     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(02)73383-6     Document Type: Article

References (18)

1. White HD, Van de Werf FJJ. Thrombolysis for acute myocardial infarction. Circulation 1998;97:1632-46
2. Armstrong PW, Granger C, Van de Werf F. Bolus fibrinolysis. Risk, benefit and opportunities. Circulation 2001;103:1171-3
3. Martínez Sande JL, González-Juanatey JR, García-Acuna JM, Amaro Cendón A, Fernández Vázquez F, Fernández López JA, et al. Influencia de la hipertensión arterial sistéma en la supervivencia a medio plazo de los pacientes con infarto agudo de miocardio que han recibidio tratamiento fibrinolitico. Med Clin (Barc) 1997;109:532-7.
4. ISIS-3 Collaborative Group. ISIS-3: a randomised comparison of strepto-kinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;333:753-70
5. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82
6. Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalbfleisch JM, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and frontloaded, accelereted alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891-8.
7. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995;346:329-36.
8. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-23.
9. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999;354:716-22.
10. The InTime-II Investigators. Intravenous NPA for the treatment of infarcting myocardium early. InTime-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of pacients with acute myocardial infarction. Eur Heart J 2000;21:2005-13.
11. Gibson CM, Cannon CP, Murphy SA, Adgey AAJ, Schweiger MJ, Sequeira RF, et al, for the TIMI 10B Investigators. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the Thrombolysis In Myocardial Infarction 10B trial. Am J Cardiol 1999;84:976-80.
12. Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, et al. Safety assessment of single-bolus administration of TNK tissue plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. Am Heart J 1999;137:786-91.
13. Tebbe U, Michels R, Adgey J, Boland J, Caspi A, Charbonnier B, et al, for the Comparison trial of Saruplase and Streptokinase (COMASS) Investigators. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: The COMPASS equivalence trial. J Am Coll Cardiol 1998;31:487-93.
14. Bar FW, Hopkins G, Dickhoet S. The bolus versus infusion in rescuepase (saruplase) development (BIRD) study in 2410 patients with acute myocardial infarction. Circulation 1998;98:1-505 [abstract].
15. Mehta SR, Eikelboom JW, Yusuf S. Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis. Lancet 2000;356:449-54.
16. Collen D, Sobel B. Intracranial haemorrhage with bolus thrombolytic agents. Lnacet 2000;356:1848.
17. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-2014.
18. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358:605-13.